Natural Killer(NK) Cell Therapy in r/r AML
Study Details
Study Description
Brief Summary
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: QN-030a QN-030a in Adult subjects with r/r AML |
Drug: QN-030a
NK cell therapy
Drug: Cyclophosphamid
Lympho-conditioning Agent
Drug: Fludarabine
Lympho-conditioning Agent
Drug: Cytarabine
Lympho-conditioning Agent
Drug: VP-16
Lympho-conditioning Agent
|
Outcome Measures
Primary Outcome Measures
- Incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability] [Up to approximately 2 years after last dose of QN-030a]
- Incidence of dose adjustment or discontinuation due to NK cell toxicities [Up to approximately 2 years after last dose of QN-030a]
- Incidence of subjects with Dose Limiting Toxicities within each dose level cohort [28 Days from first dose of QN-030a]
- Determine the Maximum tolerated dose (MTD) and RP2D [28 Days from first dose of QN-030a]
Secondary Outcome Measures
- Overall Response Rate(ORR) of QN-030a in r/r AML [Up to approximately 2 years after last dose of QN-030a]
Proportion of subjects who achieve a CR, CRi, CRMRD-, MLFS, or PR, as determined by investigator.
- Relapse-free survival (RFS) of QN-030a in r/r AML [Up to approximately 2 years after last dose of QN-030a]
- Time to Response (TTR) of QN-030a in r/r AML [Up to approximately 2 years after last dose of QN-030a]
- Event-free survival (EFS) of QN-030a in r/r AML [Up to approximately 2 years after last dose of QN-030a]
- Overall Survival (OS) of QN-030a in r/r AML [Up to approximately 2 years after last dose of QN-030a]
- Determination of the pharmacokinetics (PK) of QN-030a cells in peripheral blood [Up to approximately 2 years after last dose of QN-030a]
The PK of QN-030a in peripheral blood will be reported as the relative percentage of product (QN-030a) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points
- Evaluate the immunogenicity features of QN-030a [Up to approximately 2 years after last dose of QN-030a]
The Donor specific antibody (DSA) and T cell receptor (TCR) will be measured.
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Provision of signed and dated informed consent form (ICF)
-
≥18 years old
-
Diagnosis of r/r AML
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤1
-
Adequate organ function as defined in the protocol
-
Donor specific antibody (DSA) to QN-030a: MFI <= 2000
Key Exclusion Criteria:
-
Allergic to drug used in this study
-
Accept other anti-tumor drugs/therapies within certain time of day 0 (first QN-030a dose infusion), time window and drug defined in the protocol.
-
received systemic immunosuppressive therapy within 7 days of day 0, or likely to require systemic immunosuppressive therapy
-
Acute Promyelocytic Leukemia (APL)
-
Central nervous system Leukemia.
-
Uncontrolled, active clinically significant infection
-
Clinically significant cardiovascular disease as defined in the protocol
-
Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection
-
History of central nervous system (CNS) disease such as stroke, epilepsy.
-
Females are pregnant or lactating
-
Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The first affiliated hospital of medical college of zhejiang university | Hangzhou | Zhejiang | China | 310003 |
Sponsors and Collaborators
- Zhejiang University
- Hangzhou Qihan Biotech Co.,Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- QN030aAL